Mereo BioPharma Group plc (MREO): Cash & Equivalents
$40.99M
As of 2025-12-31
$30.12M
As of 2026-06-30
-15.6%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $40.99M | -41.3% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $69.80M | +21.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $57.42M | -15.8% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $68.18M | n/a | 2024-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $40.99M | -41.3% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $2.18M | -33.7% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $11.28M | -90.7% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $6.66M | n/a |
| PMGC Holdings Inc. (ELAB) | 2024-12-31 | $3.98M | +19.8% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $1.11M | -27.9% |
| Medicinova Inc (MNOV) | 2025-12-31 | $30.81M | -23.7% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.53M | +14.6% |
Compare MREO, LIPO, SLN, YARW side by side · Screen every company in Pharmaceutical Preparations ↗